Cisplatin

Generic Name: Cisplatin

Brand Names: Platinol

Drug Type: Small Molecule

Chemical Formula: Cl_₂H_₆N_₂Pt

CAS Number: 15663-27-1

Unique Ingredient Identifier: Q20Q21Q62J

Background: Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication: For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions: Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer

Associated Therapies: -

Clinical Trials

M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)

Phase 1

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Cisplatin
Drug: Docetaxel
Drug: Nab-paclitaxel
Drug: Carboplatin
Drug: Gemcitabine
Drug: Bintrafusp alfa
Drug: Pemetrexed
Drug: M7824
Drug: Paclitaxel

First Posted Date: 2019-02-15

Last Posted Date: 2023-08-21

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 70

Registration Number: NCT03840915

Locations: 🇺🇸
Compassionate Care Research Group Inc - Edinger Medical Group, Inc., Fountain Valley, California, United States
🇺🇸
RCCA MD LLC - Bethesda, Bethesda, Maryland, United States
🇺🇸
University of Maryland - DUPLICATE/Pediatric Surgery, Baltimore, Maryland, United States

and more 16 locations

M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

Phase 2

Terminated

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: M7824
Drug: Placebo
Drug: Durvalumab
Drug: Etoposide
Drug: Pemetrexed
Drug: Carboplatin
Drug: Paclitaxel
Drug: Cisplatin
Radiation: Intensity Modulated Radiation Therapy (IMRT)

First Posted Date: 2019-02-15

Last Posted Date: 2024-01-16

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 153

Registration Number: NCT03840902

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center - Unit 432 Thoracic Head and Neck Medical Oncology, Houston, Texas, United States
🇺🇸
Lynn Cancer Institute Center, Boca Raton, Florida, United States
🇺🇸
American Health Network of Indiana, LLC, Indianapolis, Indiana, United States

and more 101 locations

Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma

Phase 3

Recruiting

Conditions: Nasopharyngeal Carcinoma
Nasopharyngeal Neoplasms
Nasopharyngeal Diseases
Head and Neck Neoplasm

Interventions: Drug: Nimotuzumab
Drug: Cisplatin

First Posted Date: 2019-02-12

Last Posted Date: 2022-11-07

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 384

Registration Number: NCT03837808

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma

Phase 2

Recruiting

Conditions: Diffuse Large B Cell Lymphoma
High-grade B-cell Lymphoma
Transformed Lymphoma

Interventions: Drug: Rituximab
Drug: Etoposide
Drug: Vincristine
Drug: Doxorubicin
Drug: Dexamethasone
Drug: Cyclophosphamide
Drug: Lenalidomide
Drug: Cisplatin
Drug: Cytarabine

First Posted Date: 2019-02-12

Last Posted Date: 2022-01-26

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 118

Registration Number: NCT03837873

Locations: 🇨🇳
the First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳
the First Affiliated Hospital of Jilin University, Changchun, Jilin, China

and more 3 locations

Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women

Phase 2

Withdrawn

Conditions: FIGO Stage IVA Cervix Carcinoma
HIV Infection
Cervical Adenocarcinoma
Cervical Squamous Cell Carcinoma, Not Otherwise Specified
FIGO Stage IIB Cervix Carcinoma
Cervical Adenosquamous Carcinoma
FIGO Stage III Cervix Carcinoma

Interventions: Drug: Carboplatin
Procedure: Patient Monitoring
Drug: Cisplatin
Drug: Paclitaxel
Radiation: Radiation Therapy

First Posted Date: 2019-02-08

Last Posted Date: 2022-06-21

Lead Sponsor: AIDS Malignancy Consortium

Registration Number: NCT03834571

Locations: 🇿🇼
Parirenyatwa Hospital, Harare, Zimbabwe
🇿🇦
Stellenbosch University, Cape Town, South Africa
🇿🇦
University of Witwatersrand, Johannesburg, South Africa

Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)

Phase 3

Completed

Conditions: Locally Advanced Cervical Cancer

Interventions: Biological: Durvalumab
Drug: Cisplatin
Drug: Carboplatin
Radiation: external beam radiation therapy (EBRT) + brachytherapy

First Posted Date: 2019-02-05

Last Posted Date: 2024-07-26

Lead Sponsor: AstraZeneca

Target Recruit Count: 770

Registration Number: NCT03830866

Locations: 🇨🇳
Research Site, Taoyuan City, Taiwan

Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)

Phase 3

Active, not recruiting

Conditions: Nonsquamous Non-small Cell Lung Cancer

Interventions: Biological: Pembrolizumab
Drug: Carboplatin
Drug: Cisplatin
Drug: Pemetrexed
Drug: Placebo matching lenvatinib
Drug: Lenvatinib

First Posted Date: 2019-02-04

Last Posted Date: 2024-06-25

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 761

Registration Number: NCT03829319

Locations: 🇺🇸
Thomas Jefferson University Hospital ( Site 0548), Philadelphia, Pennsylvania, United States
🇵🇱
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 0603), Warszawa, Mazowieckie, Poland
🇦🇷
Sanatorio Parque ( Site 0365), Rosario, Santa Fe, Argentina

and more 155 locations

De-Escalation Radiotherapy in Patients With Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma

Phase 2

Active, not recruiting

Conditions: Oropharyngeal Cancer

Interventions: Radiation: Radiation
Drug: Cisplatin

First Posted Date: 2019-01-30

Last Posted Date: 2024-07-31

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 103

Registration Number: NCT03822897

Locations: 🇨🇦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦
Kingston Health Sciences Centre, Kingston, Ontario, Canada
🇨🇦
The Research Institute of the McGill University, Montreal, Quebec, Canada

and more 11 locations

A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC

Phase 1

Active, not recruiting

Conditions: Metastatic Non-Small Cell Lung Cancer (NSCLC)

Interventions: Drug: Durvalumab
Drug: AZD2936
Drug: MEDI5752
Drug: Pemetrexed
Drug: Oleclumab
Drug: Danvatirsen
Drug: Cisplatin
Drug: Carboplatin
Drug: Gemcitabine
Drug: Nab-paclitaxel

First Posted Date: 2019-01-28

Last Posted Date: 2024-10-22

Lead Sponsor: AstraZeneca

Target Recruit Count: 175

Registration Number: NCT03819465

Locations: 🇹🇭
Research Site, Hat Yai, Thailand

Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer

Phase 3

Suspended

Conditions: Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

Interventions: Procedure: Biospecimen Collection
Drug: Cisplatin
Procedure: Computed Tomography
Procedure: Echocardiography
Other: Fludeoxyglucose F-18
Radiation: Intensity-Modulated Radiation Therapy
Biological: Nivolumab
Other: Patient Observation
Procedure: Positron Emission Tomography

First Posted Date: 2019-01-22

Last Posted Date: 2025-01-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 636

Registration Number: NCT03811015

Locations: 🇺🇸
The Watson Clinic, Lakeland, Florida, United States
🇺🇸
Moffitt Cancer Center-International Plaza, Tampa, Florida, United States
🇺🇸
Moffitt Cancer Center - McKinley Campus, Tampa, Florida, United States

and more 728 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy